Phenytoin — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Epilepsy / Seizure Disorders

• Carbamazepine
• Gabapentin
• Lamotrigine
• Levetiracetam
• Topiramate
• Valproic Acid

Other medications in Neurology

• Selegiline Oral
• Tetrabenazine
• Deutetrabenazine

About Phenytoin

Phenytoin is a cornerstone medication for individuals managing epilepsy and certain types of seizures, playing a vital role in stabilizing brain activity. Consistent, affordable access to this prescription is essential for maintaining health and quality of life. TheDrugClub is dedicated to making crucial medications like phenytoin more accessible and budget-friendly for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Phenytoin is approved for (FDA label)

Phenytoin Infatabs are indicated for the treatment of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin Infatabs are indicated for the treatment of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: May 22, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Phenytoin (FDA label)

Phenytoin Infatabs are available as 50 mg phenytoin yellow triangular scored chewable tablets. Phenytoin Infatabs are available as 50 mg phenytoin scored chewable tablets. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3580e6a8-f7c3-44a0-a1eb-2a84ae589d21. SPL document ID: 7cdde2aa-57b2-49e4-8563-bbe86f67cd39. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Phenytoin (FDA label)

The following serious adverse reactions are described elsewhere in the labeling: • Withdrawal Precipitated Seizure, Status Epilepticus [see Warnings and Precautions (5.1) ] • Suicidal Behavior and Ideation [see Warnings and Precautions (5.2) ] • Serious Dermatologic Reactions [see Warnings and Precautions (5.3) ] • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.4) ] • Hypersensitivity [see Warnings and Precautions (5.5) ] • Cardiac Effects [see Warnings and Precautions (5.6) ] • Angioedema [see Warnings and Precautions (5.7) ] • Hepatic Injury [see Warnings and Precautions (5.8) ] • Hematopoietic Complications [see Warnings and Precautions (5.9) ] • Effects on Vitamin D and Bone [see Warnings and Precautions (5.10) ] • Exacerbation of Porphyria [see Warnings and Precautions (5.12) ] • Teratogenicity and Other Harm to the Newborn [see Warnings and Precautions (5.13) ] • Hyperglycemia [see Warnings and Precautions (5.14) ] The following adverse reactions associated with the use of phenytoin were identified in clinical studies or postmarketing reports.

Source: FDA prescribing information (DailyMed). Set ID: 3580e6a8-f7c3-44a0-a1eb-2a84ae589d21. SPL document ID: 7cdde2aa-57b2-49e4-8563-bbe86f67cd39. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Phenytoin (FDA label)

Phenytoin is contraindicated in patients with: • A history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins [see Warnings and Precautions (5.5) ] . Reactions have included angioedema. • A history of prior acute hepatotoxicity attributable to phenytoin [see Warnings and Precautions (5.8) ]. • Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors. • Hypersensitivity to phenytoin, its ingredients, or other hydantoins ( 4 , 5.5 ) • A history of prior acute hepatotoxicity attributable to phenytoin ( 4 , 5.8 ) • Coadministration with delavirdine ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3580e6a8-f7c3-44a0-a1eb-2a84ae589d21. SPL document ID: 7cdde2aa-57b2-49e4-8563-bbe86f67cd39. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Phenytoin (FDA label)

• Withdrawal Precipitated Seizure: May precipitate status epilepticus. Dose reductions or discontinuation should be done gradually. ( 5.1 ) • Suicidal Behavior and Ideation: Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. ( 5.2 ) • Serious Dermatologic Reactions: Discontinue phenytoin at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. ( 5.3 ) • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: If signs or symptoms of hypersensitivity are present, evaluate the patient immediately.

Source: FDA prescribing information (DailyMed). Set ID: 3580e6a8-f7c3-44a0-a1eb-2a84ae589d21. SPL document ID: 7cdde2aa-57b2-49e4-8563-bbe86f67cd39. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Phenytoin (FDA label)

Phenytoin is extensively bound to plasma proteins and is prone to competitive displacement. Phenytoin is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C9 and to a lesser extent by CYP2C19, and is particularly susceptible to inhibitory drug interactions because it is subject to saturable metabolism. Inhibition of metabolism may produce significant increases in circulating phenytoin concentrations and enhance the risk of drug toxicity. Monitoring of phenytoin serum levels is recommended when a drug interaction is suspected. Phenytoin is a potent inducer of hepatic drug-metabolizing enzymes. Multiple drug interactions because of extensive plasma protein binding, saturable metabolism and potent induction of hepatic enzymes. ( 7.1 , 7.2 ) 7.1 Drugs that Affect Phenytoin Concentrations Table 2 includes commonly occurring drug interactions that affect phenytoin concentrations. However, this list is not intended to be inclusive or comprehensive. Individual prescribing information from relevant drugs should be consulted.

Source: FDA prescribing information (DailyMed). Set ID: 3580e6a8-f7c3-44a0-a1eb-2a84ae589d21. SPL document ID: 7cdde2aa-57b2-49e4-8563-bbe86f67cd39. Label effective date: May 22, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.